Kyle A. Udd

467 total citations
25 papers, 307 citations indexed

About

Kyle A. Udd is a scholar working on Hematology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Kyle A. Udd has authored 25 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 13 papers in Oncology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kyle A. Udd's work include Multiple Myeloma Research and Treatments (15 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Peptidase Inhibition and Analysis (9 papers). Kyle A. Udd is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Peptidase Inhibition and Analysis (9 papers). Kyle A. Udd collaborates with scholars based in United States. Kyle A. Udd's co-authors include James R. Berenson, Tanya M. Spektor, Regina A. Swift, Mingjie Li, Haiming Chen, Eric Sanchez, Suzie Vardanyan, Cathy S. Wang, Nika M Harutyunyan and Claudia Andreu‐Vieyra and has published in prestigious journals such as Blood, Molecular Cancer Research and Supportive Care in Cancer.

In The Last Decade

Kyle A. Udd

25 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kyle A. Udd United States 8 202 197 121 99 51 25 307
Andrew Dalovisio United States 9 188 0.9× 209 1.1× 105 0.9× 115 1.2× 55 1.1× 17 297
Lauren Harvey United States 6 179 0.9× 112 0.6× 88 0.7× 64 0.6× 45 0.9× 8 258
Christie P.M. Verkleij Netherlands 12 298 1.5× 284 1.4× 158 1.3× 175 1.8× 139 2.7× 26 452
Rodica Morariu-Zamfir United States 8 232 1.1× 104 0.5× 58 0.5× 127 1.3× 96 1.9× 15 385
Nika M Harutyunyan United States 7 212 1.0× 213 1.1× 124 1.0× 118 1.2× 47 0.9× 14 312
Suzie Vardanyan United States 7 213 1.1× 223 1.1× 131 1.1× 120 1.2× 47 0.9× 20 322
Carolyn C. Jackson United States 11 308 1.5× 188 1.0× 183 1.5× 30 0.3× 90 1.8× 41 399
Jeroen Lammerts van Bueren Netherlands 7 161 0.8× 177 0.9× 102 0.8× 51 0.5× 74 1.5× 22 290
Habte Yimer United States 9 156 0.8× 136 0.7× 106 0.9× 19 0.2× 36 0.7× 48 270
Laura Montejano Spain 5 143 0.7× 254 1.3× 145 1.2× 29 0.3× 46 0.9× 7 300

Countries citing papers authored by Kyle A. Udd

Since Specialization
Citations

This map shows the geographic impact of Kyle A. Udd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle A. Udd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle A. Udd more than expected).

Fields of papers citing papers by Kyle A. Udd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle A. Udd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle A. Udd. The network helps show where Kyle A. Udd may publish in the future.

Co-authorship network of co-authors of Kyle A. Udd

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle A. Udd. A scholar is included among the top collaborators of Kyle A. Udd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle A. Udd. Kyle A. Udd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Udd, Kyle A., Sean Bujarski, Tanya M. Spektor, et al.. (2019). Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. Targeted Oncology. 14(5). 551–561. 15 indexed citations
3.
Chen, Haiming, Mingjie Li, Eric Sanchez, et al.. (2017). Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects. Molecular Cancer Research. 15(5). 598–609. 18 indexed citations
4.
Li, Mingjie, Eric Sanchez, Camilia Soof, et al.. (2017). Serum Bcma May Interfere with Anti-Bcma-CAR-Transduced T Cells or Other Anti-Bcma Antibody-Based Immunotherapy in Multiple Myeloma. Blood. 130. 4413–4413. 6 indexed citations
5.
Bujarski, Sean, Kyle A. Udd, Camilia Soof, et al.. (2017). Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments. Blood. 130. 4371–4371. 1 indexed citations
6.
7.
Sun, Clare, Camilia Soof, Sarah E. M. Herman, et al.. (2017). Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib. Blood. 130. 4031–4031. 2 indexed citations
8.
Wang, James, Tanya M. Spektor, Jacob D. Bitran, et al.. (2017). Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. Supportive Care in Cancer. 25(10). 3217–3224. 2 indexed citations
9.
Chen, Haiming, Mingjie Li, Cathy Wang, et al.. (2017). Increase in M2 Macrophage Polarization in Multiple Myeloma Bone Marrow is Inhibited with the JAK2 Inhibitor Ruxolitinib Which Shows Anti-MM Effects. Clinical Lymphoma Myeloma & Leukemia. 17(1). e93–e93. 2 indexed citations
10.
Udd, Kyle A., Tanya M. Spektor, & James R. Berenson. (2017). Monitoring multiple myeloma.. PubMed. 15(12). 951–961. 9 indexed citations
11.
Udd, Kyle A., Camilia Soof, Eric Sanchez, et al.. (2017). Changes in Serum B-Cell Maturation Antigen Levels Are a Rapid and Reliable Indicator of Treatment Efficacy for Patients with Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 17(1). e19–e20. 5 indexed citations
12.
Vardanyan, Suzie, James Wang, Nika M Harutyunyan, et al.. (2016). Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Annals of Hematology. 96(3). 449–459. 14 indexed citations
13.
Li, Mingjie, Suzie Vardanyan, Nika M Harutyunyan, et al.. (2016). Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 102(4). 785–795. 140 indexed citations
14.
Vardanyan, Suzie, James Wang, Nika M Harutyunyan, et al.. (2016). Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. Annals of Hematology. 96(3). 441–448. 6 indexed citations
15.
Wang, James, Kyle A. Udd, Regina A. Swift, et al.. (2016). Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Supportive Care in Cancer. 24(7). 3105–10. 28 indexed citations
16.
Robinson, Austin, James Wang, Suzie Vardanyan, et al.. (2016). Risk of skin cancer in multiple myeloma patients: a retrospective cohort study. European Journal Of Haematology. 97(5). 439–444. 12 indexed citations
17.
18.
Udd, Kyle A., Haiming Chen, Tanya M. Spektor, et al.. (2016). Serum CD147 Levels Are Increased in Multiple Myeloma Patients and Elevated Levels Are Associated with Refractory Disease and Shortened Progression Free Survival. Blood. 128(22). 5652–5652. 2 indexed citations
19.
Udd, Kyle A., Haiming Chen, Mingjie Li, et al.. (2016). Changes in Serum B-Cell Maturation Antigen Levels Are a More Rapid Indicator of Therapeutic Response or Disease Progression for Patients with Multiple Myeloma. Blood. 128(22). 5654–5654. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew Dalovisio Breakdown of academic impact, for papers by Lauren Harvey Breakdown of academic impact, for papers by Christie P.M. Verkleij Breakdown of academic impact, for papers by Rodica Morariu-Zamfir Breakdown of academic impact, for papers by Nika M Harutyunyan Breakdown of academic impact, for papers by Suzie Vardanyan Breakdown of academic impact, for papers by Carolyn C. Jackson Breakdown of academic impact, for papers by Jeroen Lammerts van Bueren Breakdown of academic impact, for papers by Habte Yimer Breakdown of academic impact, for papers by Laura Montejano
Rankless by CCL
2026